Serum levels of VEGF-C, VEGF-D, and sVEGF-R2 in patients with lung cancer during chemotherapy

Oncology Research

Volumn 16, Issue 9, 2007, Pages 445-451

  Naumnik, Wojciech ^a   Izycki, Tomasz ^a   Świdzińska, Ewa ^a   Ossolińska, Maria ^a   Chyczewska, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Chemotherapy; Lung cancer; Soluble VEGF receptor 2 (sVEGFR 2); VEGF C; VEGF D

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VOLUNTEER; BLOOD; LUNG TUMOR; MIDDLE AGED; SMALL CELL CARCINOMA;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 38449099107     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000007783980864     Document Type: Article

References (32)

1. Ferrara, N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 56:794-814; 1999.
2. Li, X.; Eriksson, U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int. J. Biochem. Cell Biol. 33:421-426; 2001.
3. Tanno, S.; Ohsaki, Y.; Nakanishi, K.; Toyoshima, E.; Kikuchi, K. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 46:11-19; 2004.
4. Bunone, G.; Vigneri, P.; Mariani, L.; Buto, S.; Collini, P.; Pilotti, S.; Pierotti, M. A.; Bongarzone, I. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am. J. Pathol. 155:1967-1976; 1999.
5. Kitadai, Y.; Amioka, T.; Haruma, K.; Tanaka, S.; Yoshihara, M.; Sumii, K.; Matsutani, N.; Yasui, W.; Chayama, K. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int. J. Cancer 93:662-666; 2001.
6. Kinoshita, J.; Kitamura, K.; Kabashima, A.; Saeki, H.; Tanaka, S.; Sugimachi, K. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res. Treat. 66:159-164; 2001.
7. Yonemura, Y.; Fushida, S.; Bando, E.; Kinoshita, K.; Miwa, K.; Endo, Y.; Sugiyama, K.; Partanen, T.; Yamamoto, H.; Sasaki, T. Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur. J. Cancer 37:918-923; 2001.
8. Akagi, K.; Ikeda, Y.; Miyazaki, M.; Abe, T.; Kinoshita, J.; Maehara, Y.; Sugimachi, K. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br. J. Cancer 83:887-891; 2000.
9. Hashimoto, I.; Kodama, J.; Seki, N.; Hongo, A.; Yoshinouchi, M.; Okuda, H.; Kudo, T. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br. J. Cancer 85:93-97; 2001.
10. Tsurusaki, T.; Kanda, S.; Sakai, H.; Kanetake, H.; Saito, Y.; Alitalo, K.; Koji, T. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br. J. Cancer 80: 309-313; 1999.
11. Arinaga, M.; Noguchi, T.; Takeno, S.; Chujo, M.; Miura, T.; Uchida, Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 97:457-464; 2003.
12. O-charoenrat, P.; Rhys-Evans, P.; Eccles, S. A. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 92:556-568; 2001.
13. Tamura, M.; Oda, M.; Tsunezuka, Y.; Matsumoto, I.; Kawakami, K.; Ohta, Y.; Watanabe, G. Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer. Chest 126:342-346; 2004.
14. Partanen, T.; Arola, J.; Saaristo, A.; Jussila, L.; Ora, A.; Miettinen, M.; Stacker, S.; Achen, M.; Alitalo, K. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J. 14:2087-2096; 2000.
15. Niki, T.; Iba, S.; Tokunou, M.; Yamada, T.; Matsuno, Y.; Hirohashi, S. Expression of vascular endothelial growth factors A, B. C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin. Cancer Res. 6: 2431-2439; 2000.
16. Achen, M. G.; Williams, R. A.; Minekus, M. P.; Thornton, G. E.; Stenvers, K.; Rogers, P. A. W.; Lederman, F.; Roufail, S.; Stacker, S. A. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumor angiogenesis. J. Pathol. 193:147-154; 2001.
17. Shida, A.; Fujioka, S.; Kobayashi, K.; Ishibashi, Y.; Nimura, H.; Mitsumori, N.; Yanaga, K. Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma. Int. J. Clin. Oncol. 11:38-43; 2006.
18. Duff, S. E.; Saunders, M.; McCredie, V.; Kumar, S.; O'Dwyer, S. T.; Jayson, G. C. Pre-operative plasma levels of vascular endothelial growth factor A, C and D in patients with colorectal cancer. Clin. Oncol. (R Coll. Radiol.) 17:367-371; 2005.
19. Mitsuhashi, A.; Suzuka, K.; Yamazawa, K.; Matsui, H.; Seki, K.; Sekiya, S. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer 103:724-730; 2005.
20. Molskness, T. A.; Stouffer, R. L.; Burry, K. A.; Gorrill, M. J.; Lee, D. M.; Patton, P. E. Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and -2, and angiogenin during ovarian stimulation in non-human primates and women. Hum. Reprod. 19:822-830; 2004.
21. Mathur, S. P.; Mathur, R. S.; Gray, E. A.; Lane, D.; Underwood, P. G.; Kohler, M.; Creasman, W. T. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A. Gynecol. Oncol. 98:467-483; 2005.
22. Lu, Z. Q.; Li, H. G.; Xie, D. R.; Zhang, H. Z.; Shen, X. M.; Zeng, Y. J.; Zeng, H. Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma. Ai Zheng 24:1132-1135; 2005.
23. Kabrun, N.; Buhring, H. J.; Choi, K.; Ullrich, A.; Risau, W.; Keller, G. Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development 124:2039-2048; 1997.
24. Tamura, M.; Ohta, Y. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: A possible diagnostic tool for lymph node metastasis. Cancer 98:1217-1222; 2003.
25. Bando, H.; Weich, H. A.; Horiguchi, S.; Funata, N.; Ogawa, T.; Toi, M. The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: A study with 193 cases. Oncol. Rep. 15:653-659; 2006.
26. Su, J. L.; Yang, P. C.; Shih, J. Y.; Yang, C. Y.; Wei, L. H.; Hsieh, C. Y.; Chou, C. H.; Jeng, Y. M.; Wang, M. Y.; Chang, K. J.; Hung, M. C.; Kuo, M. L. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 3:209-223; 2006.
27. Niki, T.; Iba, S.; Tokunou, M.; Yamada, T.; Matsuno, Y.; Hirohashi, S. Expression of vascular endothelial growth factor A, B, C and D and their relationships to lymph node status in lung adenocarcinoma. Clin. Cancer Res. 6:2431-2439; 2000.
28. Mouawad, R.; Meric, J. B.; Spano, J. P.; Auclerc, G.; Rixe, O.; Khayat, D.; Soubrane, C. Relationship of soluble VEGF-C and VEGF-D with clinicopathological parameters in metastatic malignant melanoma patients treated by biochemotherapy. J. Clin. Oncol. 23:16S; 2005.
29. Hu, Q.; Dey, A. L.; Yang, Y.; Shen, Y.; Jilani, I. B.; Estey, E. H.; Kantarjian, H. M.; Giles, F. J.; Albitar, M. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer 100:1884-1891; 2004.
30. Verstovsek, S.; Lunin, S.; Kantarjian, H.; Manshouri, T.; Faderl, S.; Cortes, J.; Giles, F.; Albitar, M. Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk. Res. 27:661-669; 2003.
31. Matsunaga, N.; Nakamura, K.; Yamamoto, A.; Taguchi, E.; Tsunoda, H.; Takahashi, K. Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potentialtherapeutic window. Mol. Cancer Ther. 5:80-88; 2006.
32. Korzeniewska, M.; Kolomecki, K.; Stepien, H.; Naze, M.; Stepien, T.; Kuzdak, K. Assessment of pro- and antiangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors. Endokrynol. Pol. 56: 39-44; 2005.